SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's first-half revenue reached $25.0 million, a 65.6% jump from $15.1 million in the first half of 2025, signaling robust demand for its SSi Mantra surgical robotic system.
The company's growth is primarily driven by system installations. During the second quarter, SSi Mantra installations rose 30.4% to 30 systems, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed using the platform reached 12,272, demonstrating growing clinical adoption. Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit increased 77.5% to $12.4 million, with an improved gross margin compared to the prior year.
The company is making progress on regulatory fronts that could serve as significant catalysts. SS Innovations is targeting FDA clearance for the SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. These milestones would open access to two of the world's largest medical device markets, potentially accelerating adoption and revenue growth.
Another key development is the company's achievements in telesurgery, which are expanding the clinical profile of the SSi Mantra. Telesurgery capabilities allow surgeons to perform procedures remotely, potentially increasing access to specialized surgical care in underserved regions. While telesurgery advances enhance the platform's value proposition, system installations remain the primary commercial growth driver.
The record revenue underscores the increasing acceptance of robotic-assisted surgery globally. As healthcare systems seek to improve patient outcomes and operational efficiency, robotic platforms like SSi Mantra offer a compelling solution. The company's growth trajectory suggests that it is well-positioned to capitalize on the expanding market for surgical robotics, which is projected to grow significantly in the coming years.
However, the decline in gross margin warrants attention. The margin contraction could be attributed to increased costs associated with scaling production, expansion into new markets, or competitive pricing strategies. Investors will likely monitor whether margin pressures persist as the company scales.
The company's forward-looking statements highlight potential risks, including those detailed in its SEC filings. As with any growth-stage medical technology company, execution risks remain, particularly regarding regulatory approvals and market adoption.
Overall, SS Innovations' strong financial performance and strategic milestones position it as a notable player in the surgical robotics space. The company's focus on expanding its installed base and achieving regulatory clearances will be key to sustaining momentum and delivering long-term value to stakeholders.
